Vanda Pharmaceuticals (VNDA) Capital Leases (2024 - 2026)

Vanda Pharmaceuticals has disclosed Capital Leases across 3 years of filings, most recently posting $3.8 million for Q1 2026.

• Capital Leases for Q1 2026 came in at $3.8 million, up 28.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.8 million (up 28.44% YoY), and the FY2025 annual result was $4.1 million, up 29.56% from the prior year.
• Capital Leases came in at $3.8 million for Q1 2026 at Vanda Pharmaceuticals, down from $4.1 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $4.1 million in Q4 2025 to a low of $2.8 million in Q3 2025.
• The 3-year median for Capital Leases is $3.1 million (2024), against an average of $3.3 million.
• Across the five-year window, Capital Leases climbed 29.56% in 2025 and increased 28.44% in 2026, its largest moves.
• Vanda Pharmaceuticals' Capital Leases stood at $3.1 million in 2024, then rose by 29.56% to $4.1 million in 2025, then dropped by 7.14% to $3.8 million in 2026.
• The last three Capital Leases figures came in at $3.8 million (Q1 2026), $4.1 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.